How does erlotinib inhibit EGFR?
Erlotinib (Tarceva) belongs to a class of drugs known as tyrosine kinase inhibitors. It works by blocking the function of a protein called the epidermal growth factor receptor (EGFR). The EGFR is found on the surface of many cancer cells as well as normal cells.
Does erlotinib cause unusual eyelash growth?
Epidermal growth factor receptor (EGFR) inhibitors have been widely used for the treatment of epithelial malignancies. A wide spectrum of skin toxicities have been described in patients receiving EGFR inhibitors. Trichomegaly, especially of the eyelashes is a rare side effect of this therapy.
What drugs target EGFR?
EGFR inhibitors used in NSCLC with EGFR gene mutations
- Erlotinib (Tarceva)
- Afatinib (Gilotrif)
- Gefitinib (Iressa)
- Osimertinib (Tagrisso)
- Dacomitinib (Vizimpro)
Is erlotinib a tyrosine kinase inhibitor?
Erlotinib, a small-molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has been shown to have potent antitumor effects against human non-small-cell lung cancer (NSCLC) cell growth; however, the mechanism of such an effect is not elucidated.
What erlotinib inhibits?
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva.
Does erlotinib inhibit phosphorylation?
Erlotinib suppressed the phosphorylation of Akt and ERK in HCC827 cells. However, out of the three erlotinib-resistant cell lines, only a slight inhibition of ERK phosphorylation in HCC827TR3 was observed (Fig. 1C).
What is eyelash Trichomegaly?
Introduction. Eyelash trichomegaly is defined as increase in length (12 mm or more), curling, pigmentation or thickness of eyelashes.[1,2] The term “trichomegaly” was first used by Gray in 1944. Various causes of trichomegaly include congenital, familial, acquired and drugs.
What causes EGFR mutation?
An EGFR mutation occurs when there is an error in the DNA that makes up the protein. These errors are also a type of biomarker. A biomarker is a biological molecule that can be an indicator of a certain condition or disease, according to the National Cancer Institute .
What is the mechanism of action of erlotinib?
Mechanism of Action and Pharmacodynamics Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized.
What class of drugs is erlotinib?
Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.